The role of immunohistochemistry in the diagnosis of flat urothelial lesions: A study using CK20, CK5/6, P53, Cd138, and Her2/Neu

Annals of Diagnostic Pathology

Volumn 18, Issue 1, 2014, Pages 27-32

  Jung, Sungmi ^a   Wu, Chenbo ^a   Eslami, Zohreh ^a   Tanguay, Simon ^b   Aprikian, Armen ^b   Kassouf, Wassim ^b   Brimo, Fadi ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

CD138; CK20; CK5 6; Flat urothelial lesions; HER2 Neu; Immunohistochemistry; P53

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; SYNDECAN 1;

ARTICLE; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

CD138; CK20; CK5/6; FLAT UROTHELIAL LESIONS; HER2/NEU; IMMUNOHISTOCHEMISTRY; P53;

CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KERATIN-5; KERATIN-6; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; SYNDECAN-1; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84890070033     PISSN: 10929134     EISSN: 15328198     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2013.10.006     Document Type: Article

References (29)

1. I.A. Sesterhenn Urothelial carcinoma in situ J.N. Eble, G. Sauter, J.I. Epstein, I.A. Sesterhenn, World Health Organization Classification of Tumors Pathology and genetics of tumors of the urinary system and male genital organs 2004 IARC Lyon 119 123
2. D.J. Grignon The current classification of urothelial neoplasms Mod Pathol 22 2009 S60 S69
3. L. Cheng, J.C. Cheville, R.M. Neumann, B.C. Leibovich, K.S. Egan, and B.E. Spotts Survival of patients with carcinoma in situ of the urinary bladder Cancer 85 1999 2469 2474
4. L. Cheng, J.C. Cheville, R.M. Neumann, and D.G. Bostwick Natural history of urothelial dysplasia of the bladder Am J Surg Pathol 23 1999 443 447
5. J.K. McKenney, S. Desai, C. Cohen, and M.B. Amin Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens Am J Surg Pathol 25 2001 1074 1078
6. A. Edgecombe, B.N. Nguyen, B. Djordjevic, E.C. Belanger, and K.T. Mai Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia Appl Immunohistochem Mol Morphol 20 2012 264 271
7. L.P. Kunju, C.T. Lee, J. Montie, and R.B. Shah Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia Pathol Int 55 2005 248 254
8. K. Shimada, M. Nakamura, M.A. De Velasco, M. Tanaka, Y. Ouji, and M. Miyake Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma Cancer Sci 101 2010 155 160
9. S. Gunia, S. Koch, O.W. Hakenberg, M. May, C. Kakies, and A. Erbersdobler Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa Am J Clin Pathol 136 2011 881 888
10. P. Harnden, I. Eardley, A.D. Joyce, and J. Southgate Cytokeratin 20 as an objective marker of urothelial dysplasia Br J Urol 78 1996 870 875
11. C. Mallofre, M. Castillo, V. Morente, and M. Sole Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia Mod Pathol 16 2003 187 191
12. R.L. Saylors III, D. Sidransky, and H.S. Friedman Infrequent p53 gene mutations in medulloblastomas Cancer Res 51 1991 4721 4723
13. J.S. Ross, A.D. del Rosario, H.X. Bui, B.V. Kallakury, N.T. Okby, and J. Figge Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma Mod Pathol 9 1996 854 860
14. S. Kruger, A. Mahnken, I. Kausch, and A.C. Feller P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma Eur Urol 47 2005 463 467
15. R. Moll, A. Lowe, J. Laufer, and W.W. Franke Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies Am J Pathol 140 1992 427 447
16. P. Harnden, A. Allam, A.D. Joyce, A. Patel, P. Selby, and J. Southgate Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease Histopathology 27 1995 169 174
17. A.J. Levine, J. Momand, and C.A. Finlay The p53 tumour suppressor gene Nature 351 1991 453 456
18. D. Sidransky, A. Von Eschenbach, Y.C. Tsai, P. Jones, I. Summerhayes, and F. Marshall Identification of p53 gene mutations in bladder cancers and urine samples Science 252 1991 706 709
19. R. Iggo, K. Gatter, J. Bartek, D. Lane, and A.L. Harris Increased expression of mutant forms of p53 oncogene in primary lung cancer Lancet 335 1990 675 679
20. S.J. Cina, K.J. Lancaster-Weiss, K. Lecksell, and J.I. Epstein Correlation of Ki-67 and p53 with the new World Health Organization/ International Society of Urological Pathology Classification System for Urothelial Neoplasia Arch Pathol Lab Med 125 2001 646 651
21. K. Fujimoto, Y. Yamada, E. Okajima, T. Kakizoe, H. Sasaki, and Sugimura Frequent association of p53 gene mutation in invasive bladder cancer Cancer Res 52 1992 1393 1398
22. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
23. H. Matsubara, Y. Yamada, K. Naruse, K. Nakamura, S. Aoki, and T. Taki Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization Oncol Rep 19 2008 57 63
24. M. Laé, J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, and A. Vieillefond Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients Ann Oncol 21 2010 815 819
25. C.L. Coogan, C.R. Estrada, S. Kapur, and K.J. Bloom HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder Urology 63 2004 786 790
26. M. Vershasselt-Crinquette, P. Colin, A. Ouzzane, V. Gnemmi, and Y.M. Robin Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry Appl Immunohistochem Mol Morphol 20 2012 363 366
27. H. Olsson, I.M. Fyhr, P. Hultman, and S. Jahnson HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder Scand J Urol Nephrol 46 2012 102 107
28. R. Moll, W.W. Franke, D.L. Schiller, B. Geiger, and R. Krepler The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells Cell 31 1982 11 24
29. M. Bernfield, M. Gotte, P.W. Park, O. Reizes, M.L. Fitzgerald, and J. Lincecum Functions of cell surface heparan sulfate proteoglycans Annu Rev Biochem 68 1999 729 777